DUBLIN–(BUSINESS WIRE)–The “Global Breast Cancer Liquid Biopsy Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering.
The breast cancer liquid biopsy market is poised to grow by $464.12 mn during 2022-2026, accelerating at a CAGR of 16.35% during the forecast period. The report on the breast cancer liquid biopsy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of breast cancer cases, growing focus on personalized medicine for cancer care, and increasing demand for better minimally invasive therapies.
The breast cancer liquid biopsy market analysis includes product segment and geographic landscape.
The breast cancer liquid biopsy market is segmented as below:
By Product
- Reagent Kits
- Instruments
- Services
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the programs to detect breast cancer at the early stages as one of the prime reasons driving the breast cancer liquid biopsy market growth during the next few years. Also, increasing funding or investment for liquid biopsy in breast cancer and technological advancements in the early-stage detection of breast cancer will lead to sizable demand in the market.
The report on the breast cancer liquid biopsy market covers the following areas:
- Breast cancer liquid biopsy market sizing
- Breast cancer liquid biopsy market forecast
- Breast cancer liquid biopsy market industry analysis
Key Topics Covered:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Companies Mentioned
- Bio Rad Laboratories Inc.
- Biocept Inc.
- Biodesix Inc.
- Cardiff Oncology Inc.
- Epic Sciences Inc.
- Exact Sciences Corp.
- F. Hoffmann La Roche Ltd.
- Fluxion Biosciences Inc.
- Guardant Health Inc.
- Illumina Inc.
- Isogen Life Science BV
- Johnson and Johnson
- Lucence Health Inc.
- Menarini Silicon Biosystems SpA
- MiRXES Pte Ltd.
- Myriad Genetics Inc.
- NeoGenomics Laboratories Inc.
- QIAGEN NV
- Sysmex Inostics Inc.
- Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/pt4gxf
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
